REGN 7544
Alternative Names: REGN-7544Latest Information Update: 05 Dec 2023
At a glance
- Originator Regeneron Pharmaceuticals
- Class Monoclonal antibodies; Natriuretic agents
- Mechanism of Action Atrial natriuretic factor receptor A antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 07 Aug 2023 Phase-I clinical trials in Cardiovascular disorders (In adults, In volunteers) in New Zealand (IV) (NCT05970718)
- 07 Aug 2023 Phase-I clinical trials in Cardiovascular disorders (In adults, In volunteers) in New Zealand (SC) (NCT05970718)
- 04 Aug 2023 REGN 7544 is available for licensing as of 04 Aug 2023. https://www.regeneron.com/about/collaborations